Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 5/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 2/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7123376 | 0.85 | CHRNB2 (0.74) | CHRNB2CHRNA4CHRNA1CHRNA7LMNA | |
| SCHEMBL7495819 | 0.82 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNA1CHRNA7LMNA | |
| SCHEMBL7501233 | 0.82 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNA1CHRNA7LMNA | |
| SCHEMBL7501821 | 0.80 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNA1CHRNA7L3MBTL1 | |
| SCHEMBL6323492 | 0.79 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA1CHRNA7LMNA | |
| SCHEMBL8184788 | 0.78 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNA1CHRNA7LMNA | |
| SCHEMBL6325147 | 0.77 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNA1CHRNA7LMNA | |
| SCHEMBL6325141 | 0.77 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNA1CHRNA7LMNA | |
| SCHEMBL7506033 | 0.76 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNA1CHRNA7KMT2A | |
| Thiacloprid Olefin SCHEMBL7735960 | 0.75 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA1CHRNA7LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0857725-B1 | (N-(pyridinylmethyl)-heterocyclic)-ylideneamine compounds as nicotinic acetylcholine receptor binding agents | PFIZER (US) | 2001-07-25 | — | — | EP | claimed |
| US-6020335-A | (N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents | PFIZER INC (US) | 2000-02-01 | — | — | US | claimed |
| EP-0857725-A1 | (N-(pyridinylmethyl)-heterocyclic)-ylideneamine compounds as nicotinic acetylcholine receptor binding agents | PFIZER INC. (US) | 1998-08-12 | — | — | EP | claimed |
| CN-103068242-A | Pest control agent | MEIJI SEIKA PHARMA CO LTD | 2013-04-24 | — | — | CN | disclosed |
| US-20020028809-A1 | Heterocyclic compounds having effect of activating a4beta2 nicotinic acetylcholine receptors | SUNTORY LIMITED | 2002-03-07 | — | — | US | disclosed |
| EP-1176141-A1 | HETEROCYCLIC COMPOUNDS HAVING EFFECT OF ACTIVATING NICOTINIC ACETYLCHOLINE $g(a)4$g(b)2 RECEPTOR | SUNTORY LIMITED (JP) | 2002-01-30 | — | — | EP | disclosed |
| EP-0857725-B1 | (N-(pyridinylmethyl)-heterocyclic)-ylideneamine compounds as nicotinic acetylcholine receptor binding agents | PFIZER (US) | 2001-07-25 | — | — | EP | disclosed |
| US-6020335-A | (N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents | PFIZER INC (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0857725-A1 | (N-(pyridinylmethyl)-heterocyclic)-ylideneamine compounds as nicotinic acetylcholine receptor binding agents | PFIZER INC. (US) | 1998-08-12 | — | — | EP | disclosed |
| EP-0639569-A1 | NOVEL HETEROCYCLIC COMPOUND | NIPPON SODA CO., LTD. (JP) | 1995-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028809-A1 | Heterocyclic compounds having effect of activating a4beta2 nicotinic acetylcholine receptors | CHRNA2, CHRNA7, CHRNB2 | CHRNB2 3/4885CHRNA4 8/4885CHRNA1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.